BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 21302811)

  • 21. New insights into Notch1 regulation of the PI3K-AKT-mTOR1 signaling axis: targeted therapy of γ-secretase inhibitor resistant T-cell acute lymphoblastic leukemia.
    Hales EC; Taub JW; Matherly LH
    Cell Signal; 2014 Jan; 26(1):149-61. PubMed ID: 24140475
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Leukemia-associated mutations within the NOTCH1 heterodimerization domain fall into at least two distinct mechanistic classes.
    Malecki MJ; Sanchez-Irizarry C; Mitchell JL; Histen G; Xu ML; Aster JC; Blacklow SC
    Mol Cell Biol; 2006 Jun; 26(12):4642-51. PubMed ID: 16738328
    [TBL] [Abstract][Full Text] [Related]  

  • 23. NOTCH1 mutation can be an early, prenatal genetic event in T-ALL.
    Eguchi-Ishimae M; Eguchi M; Kempski H; Greaves M
    Blood; 2008 Jan; 111(1):376-8. PubMed ID: 17901244
    [TBL] [Abstract][Full Text] [Related]  

  • 24. NOTCH1 mutations in T-cell acute lymphoblastic leukemia: prognostic significance and implication in multifactorial leukemogenesis.
    Zhu YM; Zhao WL; Fu JF; Shi JY; Pan Q; Hu J; Gao XD; Chen B; Li JM; Xiong SM; Gu LJ; Tang JY; Liang H; Jiang H; Xue YQ; Shen ZX; Chen Z; Chen SJ
    Clin Cancer Res; 2006 May; 12(10):3043-9. PubMed ID: 16707600
    [TBL] [Abstract][Full Text] [Related]  

  • 25. NOTCH1 and FBXW7 mutations have a favorable impact on early response to treatment, but not on outcome, in children with T-cell acute lymphoblastic leukemia (T-ALL) treated on EORTC trials 58881 and 58951.
    Clappier E; Collette S; Grardel N; Girard S; Suarez L; Brunie G; Kaltenbach S; Yakouben K; Mazingue F; Robert A; Boutard P; Plantaz D; Rohrlich P; van Vlierberghe P; Preudhomme C; Otten J; Speleman F; Dastugue N; Suciu S; Benoit Y; Bertrand Y; Cavé H;
    Leukemia; 2010 Dec; 24(12):2023-31. PubMed ID: 20861920
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Structure of the Notch1-negative regulatory region: implications for normal activation and pathogenic signaling in T-ALL.
    Gordon WR; Roy M; Vardar-Ulu D; Garfinkel M; Mansour MR; Aster JC; Blacklow SC
    Blood; 2009 Apr; 113(18):4381-90. PubMed ID: 19075186
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Notch-1 mutations are secondary events in some patients with T-cell acute lymphoblastic leukemia.
    Mansour MR; Duke V; Foroni L; Patel B; Allen CG; Ancliff PJ; Gale RE; Linch DC
    Clin Cancer Res; 2007 Dec; 13(23):6964-9. PubMed ID: 18056171
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Notch1 mutations are important for leukemic transformation in murine models of precursor-T leukemia/lymphoma.
    Lin YW; Nichols RA; Letterio JJ; Aplan PD
    Blood; 2006 Mar; 107(6):2540-3. PubMed ID: 16282337
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Activating mutations of NOTCH1 in human T cell acute lymphoblastic leukemia.
    Weng AP; Ferrando AA; Lee W; Morris JP; Silverman LB; Sanchez-Irizarry C; Blacklow SC; Look AT; Aster JC
    Science; 2004 Oct; 306(5694):269-71. PubMed ID: 15472075
    [TBL] [Abstract][Full Text] [Related]  

  • 30. BCL11B, FLT3, NOTCH1 and FBXW7 mutation status in T-cell acute lymphoblastic leukemia patients.
    Kraszewska MD; Dawidowska M; Kosmalska M; Sędek L; Grzeszczak W; Kowalczyk JR; Szczepański T; Witt M;
    Blood Cells Mol Dis; 2013 Jan; 50(1):33-8. PubMed ID: 23040356
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Toward a NOTCH1/FBXW7/RAS/PTEN-based oncogenetic risk classification of adult T-cell acute lymphoblastic leukemia: a Group for Research in Adult Acute Lymphoblastic Leukemia study.
    Trinquand A; Tanguy-Schmidt A; Ben Abdelali R; Lambert J; Beldjord K; Lengliné E; De Gunzburg N; Payet-Bornet D; Lhermitte L; Mossafa H; Lhéritier V; Bond J; Huguet F; Buzyn A; Leguay T; Cahn JY; Thomas X; Chalandon Y; Delannoy A; Bonmati C; Maury S; Nadel B; Macintyre E; Ifrah N; Dombret H; Asnafi V
    J Clin Oncol; 2013 Dec; 31(34):4333-42. PubMed ID: 24166518
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Diverse mutations and structural variations contribute to Notch signaling deregulation in paediatric T-cell lymphoblastic lymphoma.
    Salmerón-Villalobos J; Ramis-Zaldivar JE; Balagué O; Verdú-Amorós J; Celis V; Sábado C; Garrido M; Mato S; Uriz J; Ortega MJ; Gutierrez-Camino A; Sinnett D; Illarregi U; Carron M; Regueiro A; Galera A; Gonzalez-Farré B; Campo E; Garcia N; Colomer D; Astigarraga I; Andrés M; Llavador M; Martin-Guerrero I; Salaverria I
    Pediatr Blood Cancer; 2022 Nov; 69(11):e29926. PubMed ID: 36000950
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Characterization of activating mutations of NOTCH3 in T-cell acute lymphoblastic leukemia and anti-leukemic activity of NOTCH3 inhibitory antibodies.
    Bernasconi-Elias P; Hu T; Jenkins D; Firestone B; Gans S; Kurth E; Capodieci P; Deplazes-Lauber J; Petropoulos K; Thiel P; Ponsel D; Hee Choi S; LeMotte P; London A; Goetcshkes M; Nolin E; Jones MD; Slocum K; Kluk MJ; Weinstock DM; Christodoulou A; Weinberg O; Jaehrling J; Ettenberg SA; Buckler A; Blacklow SC; Aster JC; Fryer CJ
    Oncogene; 2016 Nov; 35(47):6077-6086. PubMed ID: 27157619
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Complexity of NOTCH1 juxtamembrane insertion mutations in T-cell acute lymphoblastic leukemia.
    Colomer-Lahiguera S; Strehl S
    Leuk Lymphoma; 2016 May; 57(5):1219-22. PubMed ID: 26292904
    [No Abstract]   [Full Text] [Related]  

  • 35. Prognostic implications of mutations in NOTCH1 and FBXW7 in childhood T-ALL treated according to the NOPHO ALL-1992 and ALL-2000 protocols.
    Fogelstrand L; Staffas A; Wasslavik C; Sjögren H; Söderhäll S; Frost BM; Forestier E; Degerman S; Behrendtz M; Heldrup J; Karrman K; Johansson B; Heyman M; Abrahamsson J; Palmqvist L
    Pediatr Blood Cancer; 2014 Mar; 61(3):424-30. PubMed ID: 24424791
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Notch1 is a frequent mutational target in chemically induced lymphoma in mouse.
    Karlsson A; Ungerbäck J; Rasmussen A; French JE; Söderkvist P
    Int J Cancer; 2008 Dec; 123(11):2720-4. PubMed ID: 18798262
    [TBL] [Abstract][Full Text] [Related]  

  • 37. NOTCH mutations as prognostic markers in T-ALL.
    Ferrando A
    Leukemia; 2010 Dec; 24(12):2003-4. PubMed ID: 21157484
    [No Abstract]   [Full Text] [Related]  

  • 38. Detection of NOTCH1 mutations in adult T-cell leukemia/lymphoma and peripheral T-cell lymphoma.
    Shimizu D; Taki T; Utsunomiya A; Nakagawa H; Nomura K; Matsumoto Y; Nishida K; Horiike S; Taniwaki M
    Int J Hematol; 2007 Apr; 85(3):212-8. PubMed ID: 17483057
    [TBL] [Abstract][Full Text] [Related]  

  • 39. RNA sequencing unravels the genetics of refractory/relapsed T-cell acute lymphoblastic leukemia. Prognostic and therapeutic implications.
    Gianfelici V; Chiaretti S; Demeyer S; Di Giacomo F; Messina M; La Starza R; Peragine N; Paoloni F; Geerdens E; Pierini V; Elia L; Mancini M; De Propris MS; Apicella V; Gaidano G; Testi AM; Vitale A; Vignetti M; Mecucci C; Guarini A; Cools J; Foà R
    Haematologica; 2016 Aug; 101(8):941-50. PubMed ID: 27151993
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Resistance mechanism to Notch inhibition and combination therapy in human T-cell acute lymphoblastic leukemia.
    Cao L; Ruiz Buendía GA; Fournier N; Liu Y; Armand F; Hamelin R; Pavlou M; Radtke F
    Blood Adv; 2023 Oct; 7(20):6240-6252. PubMed ID: 37358480
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.